Novo Nordisk to halve U.S. list price of Wegovy from 2027
Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday. The price cuts will be effective January 1 next year, coinciding with the implementation of new, lower prices for the same drugs under federal Medicare … Read more